Production (Stage)
Axsome Therapeutics, Inc.
AXSM
$105.07
$0.720.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 72.16% | 42.53% | 51.47% | 59.73% | 73.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.16% | 42.53% | 51.47% | 59.73% | 73.58% |
| Cost of Revenue | 48.33% | 27.77% | 51.76% | 85.08% | 112.85% |
| Gross Profit | 74.77% | 44.11% | 51.45% | 57.41% | 70.14% |
| SG&A Expenses | 24.51% | 27.31% | 29.24% | 45.79% | 67.47% |
| Depreciation & Amortization | -0.27% | 0.27% | 0.27% | 0.28% | 11.90% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.34% | 40.71% | 43.96% | 60.37% | 72.09% |
| Operating Income | 2.38% | -38.01% | -34.76% | -61.08% | -70.59% |
| Income Before Tax | 6.65% | -20.50% | -55.22% | -69.63% | -90.85% |
| Income Tax Expenses | 105.25% | -91.15% | -125.29% | -151.10% | -162.79% |
| Earnings from Continuing Operations | 6.11% | -20.05% | -54.07% | -67.28% | -86.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.11% | -20.05% | -54.07% | -67.28% | -86.73% |
| EBIT | 2.38% | -38.01% | -34.76% | -61.08% | -70.59% |
| EBITDA | 3.03% | -38.79% | -35.56% | -63.27% | -72.98% |
| EPS Basic | 9.65% | -15.29% | -44.44% | -52.20% | -67.92% |
| Normalized Basic EPS | 5.15% | -30.95% | -24.35% | -41.01% | -48.09% |
| EPS Diluted | 9.58% | -15.29% | -44.44% | -52.20% | -67.92% |
| Normalized Diluted EPS | 5.15% | -30.95% | -24.35% | -41.01% | -48.09% |
| Average Basic Shares Outstanding | 4.11% | 5.51% | 7.13% | 9.90% | 10.58% |
| Average Diluted Shares Outstanding | 4.11% | 5.51% | 7.13% | 9.90% | 10.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |